undamentalytics Newsletter
Sign in

China SXT Pharmaceuticals, Inc. (SXTC) stock

Add to watchlist

Add holding +

NASDAQ: SXTC Nasdaq Pharmaceuticals

E Fundamentals grade

China SXT Pharmaceuticals, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in March.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for China SXT Pharmaceuticals, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: cash-flow, stock-pay or share-count figures missing or out of date. We'll show the comparison once resolved.

China SXT Pharmaceuticals, Inc. valuation: adjust assumptions and compare models →

Value diary

Our note on each quarter China SXT Pharmaceuticals files

Where China SXT Pharmaceuticals stands after its latest Filing

China SXT Pharmaceuticals has little or no product revenue yet; it used $4m of cash in the twelve months. That puts it 68 of 74 for growth among the pharmaceuticals companies we cover. The diluted share count is up 7062.5% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 4 of our 7 financial-health checks.

Our model value for China SXT Pharmaceuticals is under review, so past values are not shown until it is resolved.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

China SXT Pharmaceuticals, Inc.'s trailing-twelve-month revenue fell 34.6% year on year, with a free-cash-flow margin of -353.0%. Where it stands out: long-term debt as % of assets of 1.9% ranks 7 of 53 pharmaceuticals companies we cover. Where it lags: change in share count of 7062.5% ranks 62 of 62 pharmaceuticals companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -34.6% (-24.9pp vs the prior quarter), the 2nd consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 34.6% over the last 12 months.
  • Growth slowing. The growth rate is 24.9 points lower than a quarter earlier.
  • Loss-making. Operating margin is -625.9%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 471.9 points on a year ago.
  • Burning cash. Free cash flow was -353.0% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 466.2% of revenue, against a median of 3.6% for pharmaceuticals companies we cover: a real cost that cash-flow figures leave out.

Price chart

  • 1 day-14.5%
  • 1 week-21.5%
  • 1 month-98.8%
  • This year-100.0%
  • 1 year-100.0%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.1M
Operating margin
-625.9%
Net margin
-545.2%
EPS (TTM, diluted)
$-9.13

Growth

Revenue growth
−34.6%
Change in growth rate
−24.9 pts
Share count change
+7062.5%

Cash

Free cash flow (TTM)
-$4M
FCF margin
-353.0%
Stock pay % of revenue
466.2%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for SXTC from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

China SXT Pharmaceuticals, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: cash-flow, stock-pay or share-count figures missing or out of date.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value China SXT Pharmaceuticals, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 7.6%: the 10-year Treasury yield (4.9%) plus a beta of 0.6 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.0 ~$1.7–$7.4 Left out: out of range vs price (0.00x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare China SXT Pharmaceuticals, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20192020202120222023202420252026
Share price$818400000.00$67200000.00$55200000.00$8400000.00$8520000.00$2016000.00$2994000.00$13440.00
Market value$1.12tn$110.8bn$10.6bn$2.3bn$1.9bn$1.5bn$28.4bn$9.1bn
+ Net debt (− = net cash)−$9m−$599667−$13m−$16m−$17m−$12m−$18m−$27m
Enterprise value$1.12tn$110.8bn$10.6bn$2.3bn$1.9bn$1.4bn$28.4bn$9.1bn
Multiples
Price / sales n/mn/mn/mn/mn/mn/mn/mn/m
Price / earnings n/m———————
Price / free cash flow —n/m—n/m————
EV / EBITDA n/m———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for China SXT Pharmaceuticals, Inc.: too few analysts cover it.

Positioning

Short interest
7.0%
of tradable shares
Days to cover
0.03
at average volume
Short interest, 1 month
+1001%
to October 15, 2026
Held by institutions
0%
of shares
Held by insiders
2.3%
of shares
Employees
56
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
SXTC−51%−17%−71%−87%+215%−100%
Industry peers (median)−18%−52%−13%−2%+7%−12%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
SXTC17%33%33%42%42%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
SXTC−89%−83%−89%−92%−82%−100%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since January 4, 2019: 100% from January 9, 2019 to November 2, 2026. Getting back needed a 51582735069% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.78 – $2400000.00
From 52-week high
−100.0%
vs 50-day average
−98.3%
vs 200-day average
−100.0%
Volatility (1 year)
304%
Beta vs S&P 500
3.36

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

China SXT Pharmaceuticals, Inc. in five measures

Fundamentals grade E
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) China SXT Pharmaceuticals, Inc.
$0 $2M $4M $6M $8M FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY26 Q4 Revenue (TTM), FY17 Q4: $4.9M Revenue (TTM), FY18 Q4: $7M Revenue (TTM), FY19 Q4: $7M Revenue (TTM), FY20 Q4: $5.2M Revenue (TTM), FY21 Q4: $4.8M Revenue (TTM), FY22 Q4: $2.6M Revenue (TTM), FY23 Q4: $2M Revenue (TTM), FY24 Q4: $1.9M Revenue (TTM), FY25 Q4: $1.7M Revenue (TTM), FY26 Q4: $1.1M $1.1M

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue (TTM)
FY17 Q4 $4.9M
FY18 Q4 $7M
FY19 Q4 $7M
FY20 Q4 $5.2M
FY21 Q4 $4.8M
FY22 Q4 $2.6M
FY23 Q4 $2M
FY24 Q4 $1.9M
FY25 Q4 $1.7M
FY26 Q4 $1.1M
Revenue growth, TTM YoY China SXT Pharmaceuticals, Inc.
-50% 0% 50% FY18 Q4 FY20 Q4 FY22 Q4 FY24 Q4 FY26 Q4 Revenue growth, TTM YoY, FY18 Q4: 43.8% Revenue growth, TTM YoY, FY19 Q4: -0.1% Revenue growth, TTM YoY, FY20 Q4: -26.4% Revenue growth, TTM YoY, FY21 Q4: -7.5% Revenue growth, TTM YoY, FY22 Q4: -45.5% Revenue growth, TTM YoY, FY23 Q4: -24.2% Revenue growth, TTM YoY, FY24 Q4: -2.2% Revenue growth, TTM YoY, FY25 Q4: -9.7% Revenue growth, TTM YoY, FY26 Q4: -34.6% -34.6%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue growth, TTM YoY
FY18 Q4 43.8%
FY19 Q4 -0.1%
FY20 Q4 -26.4%
FY21 Q4 -7.5%
FY22 Q4 -45.5%
FY23 Q4 -24.2%
FY24 Q4 -2.2%
FY25 Q4 -9.7%
FY26 Q4 -34.6%
Operating margin (TTM) China SXT Pharmaceuticals, Inc.
-800% -600% -400% -200% 0% 200% FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY26 Q4 Operating margin (TTM), FY17 Q4: 32.8% Operating margin (TTM), FY18 Q4: 23.3% Operating margin (TTM), FY19 Q4: 25.2% Operating margin (TTM), FY20 Q4: -26.0% Operating margin (TTM), FY21 Q4: -46.0% Operating margin (TTM), FY22 Q4: -199.4% Operating margin (TTM), FY23 Q4: -284.4% Operating margin (TTM), FY24 Q4: -130.4% Operating margin (TTM), FY25 Q4: -154.0% Operating margin (TTM), FY26 Q4: -625.9% -625.9%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Operating margin (TTM)
FY17 Q4 32.8%
FY18 Q4 23.3%
FY19 Q4 25.2%
FY20 Q4 -26.0%
FY21 Q4 -46.0%
FY22 Q4 -199.4%
FY23 Q4 -284.4%
FY24 Q4 -130.4%
FY25 Q4 -154.0%
FY26 Q4 -625.9%
FCF margin (TTM) China SXT Pharmaceuticals, Inc.
-400% -300% -200% -100% 0% 100% FY17 Q4 FY19 Q4 FY21 Q4 FY24 Q4 FY26 Q4 FCF margin (TTM), FY17 Q4: 2.3% FCF margin (TTM), FY18 Q4: 21.1% FCF margin (TTM), FY19 Q4: -4.2% FCF margin (TTM), FY20 Q4: 15.6% FCF margin (TTM), FY21 Q4: -29.2% FCF margin (TTM), FY22 Q4: 8.0% FCF margin (TTM), FY24 Q4: -100.3% FCF margin (TTM), FY25 Q4: -134.8% FCF margin (TTM), FY26 Q4: -353.0% -353.0%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period FCF margin (TTM)
FY17 Q4 2.3%
FY18 Q4 21.1%
FY19 Q4 -4.2%
FY20 Q4 15.6%
FY21 Q4 -29.2%
FY22 Q4 8.0%
FY24 Q4 -100.3%
FY25 Q4 -134.8%
FY26 Q4 -353.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F, 20-F/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2017 Mar 2017 2018 Mar 2018 2019 Mar 2019 2020 Mar 2020 2021 Mar 2021 2022 Mar 2022 2023 Mar 2023 2024 Mar 2024 2025 Mar 2025 2026 Mar 2026
Income
Revenue 5 7 7 5 5 3 2 2 2 1
Gross profit 2 3 5 3 3 1 0 1 0 0
EBITDA 2 2 2 −1 −2 −5 −5 −2 −3 −7
Operating income 2 2 2 −1 −2 −5 −6 −3 −3 −7
Net income 1 1 2 −10 −3 −6 −6 −3 −3 −6
Diluted EPS $885.00 $885.00 $1125.00 $6240.00 −$14321.25 −$20687.70 −$26675.55 −$4285.66 −$348.17 −$9.13
Growth (year on year)
Revenue — +43.8% −0.1% −26.4% −7.5% −45.5% −24.2% −2.2% −9.7% −34.6%
EBITDA — +3.8% +10.7% −151.7% — — — — — —
Operating income — +1.9% +8.4% −175.8% — — — — — —
Net income — +0.2% +29.6% −768.4% — — — — — —
Diluted EPS — 0.0% +27.1% +454.7% — — — — — —
Margins
Gross margin 47.4% 48.5% 65.8% 52.4% 59.4% 48.1% 21.6% 28.7% 21.1% 21.9%
EBITDA margin 34.8% 25.1% 27.8% −19.6% −38.8% −187.1% −271.7% −119.9% −149.2% −619.4%
Operating margin 32.8% 23.3% 25.2% −26.0% −46.0% −199.4% −284.4% −130.4% −154.0% −625.9%
Net margin 24.3% 16.9% 22.0% −199.3% −57.5% −220.4% −301.0% −160.7% −189.8% −545.2%
Free-cash-flow margin 2.3% 21.1% −4.2% 15.6% −29.2% 8.0% — −100.3% −134.8% −353.0%
Cash flow
Cash from operations 0 2 0 1 −1 0 −0 −2 −2 −4
Capital spending 0 0 1 0 0 0 — 0 0 0
Free cash flow 0 1 −0 1 −1 0 — −2 −2 −4
Stock-based pay — — — — — 2 1 0 — 5
Free cash flow after stock pay — — — — — −2 — −2 — −9
Balance sheet
Cash 0 1 9 7 13 16 17 12 18 28
Total debt 0 0 0 7 0 — — — — 1
Net debt (negative = net cash) −0 −0 −9 −1 −13 −16 −17 −12 −18 −27
Diluted shares — — — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 7 checks passed · March 31, 2026
What it owns · $35m
Short-term assets $35mLonger-term assets $0m
What it owes, and who funded it · $35m
Short-term liabilities $4mLonger-term liabilities $1mShareholders' equity $30m
  • Short-term assets cover short-term liabilities $35m of assets due within a year against $4m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $35m short-term assets against $697,832 of longer-dated liabilities.
  • More cash than debt $28m of cash against $999,565 of debt.
  • Debt below 40% of shareholders' equity Debt is 3% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 3% over five years.
  • A year's operating cash flow covers at least 20% of debt −$4m of operating cash flow against $999,565 of debt.
  • Operating profit covers interest at least five times over Operating income of −$7m against $62,965 of interest.

From China SXT Pharmaceuticals, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+7062.5%
year over year
Days sales outstanding
299 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated SXTC SXTP LPCN SCNX NTRB EYPT Median
Revenue, last 12 months $1m $1m $2m $821315 $2m $3m $276m
Revenue growth, last 12 months −34.6% 73.2% −62.7% 540.6% −37.3% −94.6% 9.9%
Revenue growth, 3-year average — 74.9% 205.6% −58.5% −10.8% −57.9% 5.5%
Revenue growth, latest quarter — 106.0% −69.5% 449.1% −29.7% −90.5% 6.5%
Gross margin 21.9% 19.4% — 87.7% 33.1% — 62.0%
Operating margin −625.9% −774.9% −800.8% <−999% −435.6% <−999% −5.9%
Operating margin, 3-year average −267.4% <−999% −378.5% <−999% −396.6% <−999% −7.4%
Net margin −545.2% −729.9% −755.1% <−999% −430.4% <−999% −7.3%
Cash from operations / revenue −353.0% −789.8% −713.0% <−999% −224.5% <−999% 10.2%
Free-cash-flow margin −353.0% −800.6% −713.0% <−999% −224.5% <−999% 8.6%
Free-cash-flow margin, 3-year average −126.6% — −309.9% <−999% −217.5% <−999% 7.4%
Stock pay / revenue 466.2% 37.2% 14.6% 257.1% 65.9% >999% 3.6%
Change in share count >999% — 25.2% 2.1% 8.9% 4.2% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth -34.6% 10.0% 68 of 74
Change in growth rate Growth -24.9pp -0.3pp 67 of 74
Gross margin Profitability 21.9% 59.8% 50 of 59
Operating margin Profitability -625.9% -5.9% 59 of 67
Net margin Profitability -545.2% -7.3% 68 of 75
Free-cash-flow margin Cash generation -353.0% 10.1% 67 of 74
Stock pay as % of revenue Cash generation 466.2% 3.6% 66 of 69
Long-term debt as % of assets Balance sheet 1.9% 23.8% 7 of 53
Change in share count Balance sheet 7062.5% 1.5% 62 of 62
Days sales outstanding Balance sheet 299 days 72 days 58 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Data status

When each part of this page on China SXT Pharmaceuticals, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

China SXT Pharmaceuticals, Inc. in brief

What does China SXT Pharmaceuticals, Inc. do?
China SXT Pharmaceuticals, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in March.
What is China SXT Pharmaceuticals, Inc.'s stock ticker?
China SXT Pharmaceuticals, Inc. trades under the ticker SXTC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is China SXT Pharmaceuticals, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, China SXT Pharmaceuticals, Inc. reported revenue of $1.1M, 34.6% lower than a year earlier, according to its SEC filings.
What is China SXT Pharmaceuticals, Inc.'s free cash flow?
China SXT Pharmaceuticals, Inc.'s free-cash-flow margin is -353.0% of revenue over the trailing twelve months, ranking 67 of the 74 pharmaceuticals companies we cover.
What is China SXT Pharmaceuticals, Inc.'s market cap?
On March 31, 2026, China SXT Pharmaceuticals, Inc.'s market capitalisation was about $9.1B and net debt of -$27.2M. Market figures come from third-party market data and may be delayed.
How much debt does China SXT Pharmaceuticals, Inc. have?
China SXT Pharmaceuticals, Inc.'s debt-to-equity ratio is 3.4%, from its latest balance sheet (0.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are China SXT Pharmaceuticals, Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to China SXT Pharmaceuticals, Inc. are 60 Degrees Pharmaceuticals, Inc., Lipocine Inc., Scienture Holdings, Inc., Nutriband Inc. and Eyepoint, Inc. The side-by-side comparison below sets their revenue, margins and growth against China SXT Pharmaceuticals, Inc.'s.